Hepatitis Research Today is a free monthly online journal that collates and summarizes the latest research about Hepatitis, including details on hepatitis a, b, c, causes, symptoms.

Immunological and virological responses to cART in HIV/HBV co-infected patients from a multicenter cohort.

Wang H, Li Y, Zhang C, Han Y, Zhang X, Zhu T, Li T

Department of Infectious Diseases, Peking Union Medical College Hospital, Beijing, China.

Published 1 April 2013 in AIDS, 26(14): 1755-63.
Full-text of this article is available online (may require subscription).

Articles on Hepatitis published 26 February 2013:

Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C.   Cochrane Database Syst Rev, 1: CD003617.

[Abstract] [Full-text]

Articles on Hepatitis published 13 February 2013:

Association between HBX status, aflatoxin-induced R249S TP53 mutation and risk of hepatocellular carcinoma in a case-control study from Thailand.   Cancer Lett, 331(1): 46-51.

Hepatocellular carcinoma (HCC) is associated with hepatitis B virus (HBV) chronicity and dietary exposure to aflatoxin, a mutagen targeting codon 249 of tumor suppressor TP53 (R249S mutation). Based on a case-control in Thailand, we have measured R249S and the status of HBX gene in plasma DNA of 176 cases and 133 referents. Detection of HBX complete sequences was associated with R249S in HCC with no documented prior cirrhosis but not in HCC developing in a context of cirrhosis or in non-cancer ... [Abstract] [Full-text]

Articles on Hepatitis published 12 February 2013:

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.   Lancet, 381(9865): 468-75.

[Abstract] [Full-text]

Articles on Hepatitis published 8 February 2013:

HBV-related events after allogeneic hematopoetic stem cell transplantatıon in a center from Turkey.   Ann Hematol, 92(3): 395-402.

To investigate the frequency of hepatitis B virus (HBV)-related events after allogeneic HCT in a moderate endemic area for HBV infection. The data of 197 patients who underwent allogeneic hematopoetic stem cell transplatation (HCT) from September 2003 through December 2010 were reviewed retrospectively with respect to HBV-related events. Resolved HBV infection was described as negative HBsAg, positive HBcAb, and positive HBsAb. Latent HBV infection was defined in patients with HBcAb positivity ... [Abstract] [Full-text]

Articles on Hepatitis published 7 February 2013:

Immune responses to hepatitis C virus (HCV) infection and the prospects for an effective HCV vaccine or immunotherapies.   J Infect Dis, 207: S7-S12.

Infection with hepatitis C virus (HCV) typically leads to persistent infection, with >170 million people estimated to be affected worldwide, putting them at risk for chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Importantly, 20%-30% of individuals are able to control the virus spontaneously, usually within 6 months of exposure. This suggests that HCV vaccines and immunotherapies are a distinct possibility. We discuss here the role of T cells in controlling HCV, the gaps ... [Abstract] [Full-text]

HIV and hepatitis C virus: special concerns for patients with cirrhosis.   J Infect Dis, 207: S40-4.

Since the advent of highly active antiretroviral therapy, liver disease has been a major cause of morbidity and mortality in patients with human immunodeficiency virus (HIV) infection. Chronic viral hepatitis accounts for >80% of liver-related mortality. Liver-related morbidity is due to acceleration of hepatitis C virus (HCV) disease, drug-induced hepatotoxicity, and, possibly, direct damage from HIV infection itself. As a consequence of this complex interaction, end-stage liver disease and ... [Abstract] [Full-text]

Antiviral resistance and the future landscape of hepatitis C virus infection therapy.   J Infect Dis, 207: S33-9.

The addition of hepatitis C virus (HCV) protease inhibitors (PIs) to interferon and ribavirin therapy has significantly improved the efficacy of treatment for HCV infection. However, for patients who do not respond to therapy, the selection of HCV variants with resistance to PIs is likely. Resistant variants, such as R155K and A156T/V, result in extensive cross-resistance to other HCV PIs. Despite the rapid and frequent appearance of PI-resistant HCV variants, the long-term clinical ... [Abstract] [Full-text]

Current management of hepatitis C virus infection in patients with HIV co-infection.   J Infect Dis, 207: S26-32.

As a result of shared routes of transmission, coinfection with hepatitis C virus (HCV) is common in human immunodeficiency virus (HIV)-infected patients. The prevalence of HIV/HCV coinfection is particularly high among persons who have used injection drugs; however, more recently, sexual transmission of HCV has been recognized among HIV-infected men who have sex with men (MSM). Over the past decade, the effectiveness of HIV treatment improved substantially, leading to a substantial reduction in ... [Abstract] [Full-text]

© 2006-2013 Hepatitis Research Today. All Rights Reserved.